利妥昔单抗对比激素联合环磷酰胺治疗特发性膜性肾病的安全性
该回顾性观察性队列研究比较了100例利妥昔单抗治疗与103例激素联合周期性环磷酰胺治疗的特发性膜性肾病患者,中位随访40个月。利妥昔单抗组不良事件(包括严重和非严重)显著少于激素联合环磷酰胺组,但部分缓解累积发生率较低,完全缓解和复合肾脏终点无显著差异。
要点
- 利妥昔单抗组不良事件总数及严重/非严重事件均显著低于激素联合环磷酰胺组。
- 利妥昔单抗组任何首次不良事件、严重不良事件、非严重不良事件的累积发生率均显著更低。
- 两组完全缓解率和复合肾脏终点(血肌酐翻倍、ESRD或死亡)无显著差异。
核心结论
- 利妥昔单抗安全性优于激素联合环磷酰胺,可能作为特发性膜性肾病伴肾病综合征患者的一线免疫抑制治疗替代方案。
研究设计与样本
- 回顾性观察性队列研究,纳入100例利妥昔单抗治疗患者和103例激素联合周期性环磷酰胺治疗患者,中位随访40个月,采用标准化方案监测并用Cox回归校正基线特征。
主要发现
- 利妥昔单抗组不良事件总数63例次,激素联合环磷酰胺组173例次(P<0.001);严重不良事件分别为11例次和46例次(P<0.001);非严重不良事件分别为52例次和127例次(P<0.001)。
- 任何首次不良事件累积发生率利妥昔单抗组35.5% vs 激素联合环磷酰胺组69.0%(P<0.001);严重不良事件16.4% vs 30.2%(P=0.002);非严重不良事件23.6% vs 60.8%(P<0.001)。
- 利妥昔单抗组对比激素联合环磷酰胺组的校正风险比(95%CI):任何首次不良事件0.27(0.16-0.44),严重不良事件0.32(0.15-0.68),非严重不良事件0.23(0.13-0.41)。
- 利妥昔单抗组部分缓解累积发生率较低,但完全缓解率和复合肾脏终点(血肌酐翻倍、ESRD或死亡)两组无显著差异。
临床怎么用
- 对于特发性膜性肾病伴肾病综合征且进展风险高的患者,可考虑将利妥昔单抗作为激素联合环磷酰胺的替代一线免疫抑制治疗,因其安全性更优。
局限性
- 回顾性观察性设计,可能存在残余混杂;部分缓解率在利妥昔单抗组较低,需权衡疗效与安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Guidelines recommend steroid plus cyclical cyclophosphamide (St-Cp) therapy for patients with idiopathic membranous nephropathy at high risk of progression to ESRD. Rituximab (Rtx) may be a safer alternative. In this retrospective, observational cohort study, we compared time to any adverse event (primary outcome); serious or nonserious events; partial and complete remission of the nephrotic syndrome; and a composite of doubling of serum creatinine, ESRD, or death between 100 Rtx-treated patients and 103 patients who received daily St-Cp We monitored patients with standardized protocols and adjusted for baseline characteristics by Cox regression. Over a median follow-up of 40 months, the Rtx group had significantly fewer adverse events than the St-Cp group (63 versus 173; P<0.001), both serious (11 versus 46; P<0.001) and nonserious (52 versus 127; P<0.001). Cumulative incidence of any first (35.5% versus 69.0%; P<0.001), serious (16.4% versus 30.2%; P=0.002), or nonserious (23.6% versus 60.8%; P<0.001) event was significantly lower with Rtx Adjusted hazard ratios (95% confidence intervals) between Rtx and St-Cp groups were 0.27 (0.16 to 0.44) for any first adverse event, 0.32 (0.15 to 0.68) for serious adverse events, and 0.23 (0.13 to 0.41) for nonserious adverse events. Although the cumulative incidence of partial remission was lower in the Rtx group, rates of complete remission and the composite renal end point did not differ significantly between groups. Because of its superior safety profile, we suggest that Rtx might replace St-Cp as first-line immunosuppressive therapy in patients with idiopathic membranous nephropathy and nephrotic syndrome.
引用
- van den Brand JAJG, Ruggenenti P, Chianca A, et al. Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy. J Am Soc Nephrol. 2017. PMID: 28487395. doi:10.1681/ASN.2016091022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。